PRINCETON, NJ – Mar. 9, 2017 – Certara today announced the launch of Simcyp Access, a new cloud-based licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.
PRINCETON, NJ – Dec. 8, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced the release of version 15 of its Simcyp® Population-based Simulator. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically-based pharmacokinetic (PBPK) modeling and simulation platform for determining first-in-human dose selection, predicting drug-drug interactions (DDIs), understanding drug disposition […]
PRINCETON, NJ – Jan. 10, 2017 – Certara today announced that it has released version 16 of its Simcyp Population-based Simulator. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating new drug formulations, and predicting drug-drug interactions (DDIs) and pharmacokinetic (PK) outcomes in clinical populations.
New release further expands biologics capabilities and provides new tools for formulation scientists ST. LOUIS, MO – Aug. 28, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that version 13 of its Simcyp™ Simulator has now been released, […]
PRINCETON, NJ – July 20, 2016 – Mitsubishi Tanabe, the 34th leading biopharmaceutical company and the tenth leading Japanese pharmaceutical company, has joined Certara’s Simcyp Consortium and licensed its proprietary Simcyp Population-based Simulator.
Acquisition will add powerful preclinical research capability to Certara’s translational science approach to drug development. ST. LOUIS, MO – February 24, 2012 – Certara™, a leading provider of drug discovery and development software and scientific consulting services and a Vector portfolio company, today announced agreement to acquire Simcyp Limited. Simcyp is a UK-based, leading research company […]
It may be 2016, but we just held the 17th annual Simcyp Consortium meeting in Sheffield, UK. This year’s gathering had >120 attendees with representatives from all but one of the 34 consortium member companies joining. The opening session reviewed the progress made by the Simcyp staff toward the field of regulatory science, physiologically-based pharmacokinetic […]
Acquisition of Simcyp adds important predictive science methodologies to Certara’s translational science approach to drug development. ST. LOUIS, MO –March 13, 2012 – Certara™, a Vector Capital portfolio company and a leading provider of drug discovery and development software and scientific consulting services, today announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp […]
Did you know that only a small fraction of the tens of thousands of commercially-used chemicals have undergone toxicological assessment? Time and cost constraints, not to mention the ethical impossibility of studying these chemicals in human trials, hamper large-scale toxicological assessment. Physiologically-based toxicokinetic (PBTK) models can be leveraged to predict TK from in vitro measurements […]
PRINCETON, NJ – Nov. 10, 2016 – Certara today announced that the U.S. Environmental Protection Agency (EPA) is using its Simcyp Population-based Simulator to support the Agency’s high-throughput toxicity testing program.